Myeloid cell leukemia-1 as a candidate prognostic biomarker in cancers: a systematic review and meta-analysis

References

• Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–791. doi: 10.1097/CM9.0000000000001474
   PubMed Web of Science ®Google Scholar
• Wang H, Guo M, Wei H, et al. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14(1):67. doi: 10.1186/s13045-021-01079-1
   PubMed Web of Science ®Google Scholar
• Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477–482. doi: 10.1038/nature19830
   PubMed Web of Science ®Google Scholar
• Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2019;33(4):905–917. doi: 10.1038/s41375-018-0261-3
   PubMed Web of Science ®Google Scholar
• Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32(1):102–110. doi: 10.1038/leu.2017.179
   PubMed Web of Science ®Google Scholar
• Chen G, Park D, Magis AT, et al. Mcl-1 interacts with Akt to promote lung cancer progression. Cancer Res. 2019;79(24):6126–6138. doi: 10.1158/0008-5472.CAN-19-0950
   PubMed Web of Science ®Google Scholar
• Ow TJ, Thomas C, Fulcher CD, et al. Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma. Laryngoscope. 2020;130(11):2643–2649. doi: 10.1002/lary.28441
   PubMed Web of Science ®Google Scholar
• Lin J, Fu D, Dai Y, et al. Mcl-1 inhibitor suppresses tumor growth of esophageal squamous cell carcinoma in a mouse model. Oncotarget. 2017;8(70):114457–114462. doi: 10.18632/oncotarget.18772
   PubMedGoogle Scholar
• Chen C, Zhu S, Zhang X, et al. Targeting the synthetic vulnerability of PTEN-Deficient glioblastoma cells with MCL1 inhibitors. Mol Cancer Ther. 2020;19(10):2001–2011. doi: 10.1158/1535-7163.MCT-20-0099
   PubMed Web of Science ®Google Scholar
• Chen J, Liao Y, Fan X. Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis. Expert Rev Anticancer Ther. 2021;21(7):795–803. doi: 10.1080/14737140.2021.1908132
   PubMed Web of Science ®Google Scholar
• Guo L, Tang Y, Wang Y, et al. Prognostic value of lncRNA NEAT1 as a new biomarker in digestive system tumors: a systematic study and meta-analysis. Expert Rev Mol Diagn. 2021;21(1):91–99. doi: 10.1080/14737159.2021.1874921
   PubMed Web of Science ®Google Scholar
• Baekelandt M, Holm R, Nesland JM, et al. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol. 2000;18(22):3775–3781. doi: 10.1200/JCO.2000.18.22.3775
   PubMed Web of Science ®Google Scholar
• Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood. 2008;112(9):3807–3817. doi: 10.1182/blood-2008-05-157131
   PubMed Web of Science ®Google Scholar
• Yin J, Li Y, Zhao H, et al. Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population. Cancer Med. 2016;5(9):2171–2179. doi: 10.1002/cam4.774
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi: 10.1007/s10654-010-9491-z
   PubMed Web of Science ®Google Scholar
• Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med. 2001;20(23):3625–3633. doi: 10.1002/sim.1091
   PubMed Web of Science ®Google Scholar
• Fletcher J. What is heterogeneity and is it important. BMJ. 2007;334(7584):94–96. doi: 10.1136/bmj.39057.406644.68
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991–996. doi: 10.1016/j.jclinepi.2007.11.010
   PubMed Web of Science ®Google Scholar
• XX L, JD Z, XM W, et al. Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia. Onco Targets Ther. 2019;12:3295–3304.
   PubMed Web of Science ®Google Scholar
• Luo W, Nagaria TS, Sun H, et al. Expression and potential prognostic value of SOX9, MCL-1 and SPOCK1 in gastric adenocarcinoma. Pathol Oncol Res. 2022;28:1610293. doi:10.3389/pore.2022.1610293
   PubMed Web of Science ®Google Scholar
• Maeta Y, Tsujitani S, Matsumoto S, et al. Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma. Gastric Cancer. 2004;7(2):78–84. doi: 10.1007/s10120-004-0272-9
   PubMedGoogle Scholar
• Nakano T, Go T, Nakashima N, et al. Overexpression of antiapoptotic MCL-1 predicts worse overall survival of patients with non-small cell lung cancer. Anticancer Res. 2020;40(2):1007–1014. doi: 10.21873/anticanres.14035
   PubMed Web of Science ®Google Scholar
• Tang Y, Yang Y, Luo J, et al. Overexpression of HSP10 correlates with HSP60 and Mcl-1 levels and predicts poor prognosis in non-small cell lung cancer patients. Cancer Biomark. 2021;30(1):85–94. doi: 10.3233/CBM-200410
   PubMed Web of Science ®Google Scholar
• Likui W, Qun L, Wanqing Z, et al. Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. J Surg Oncol. 2009;100(5):396–400. doi: 10.1002/jso.21344
   PubMed Web of Science ®Google Scholar
• Biwei W, Hui S, Xi C, et al. Expression and clinical significance of IL-6，IL-6R and MCL-1 in patients with multiple myeloma. J Exp Hematol. 2020;28(2):553–557.
   Google Scholar
• Wang W, Yin X, Li G, et al. Expressions of farnesoid X receptor and myeloid cell leukemia sequence 1 protein are associated with poor prognosis in patients with gallbladder cancer. Chin Med J (Engl). 2014;127(14):2637–2642.
   PubMed Web of Science ®Google Scholar
• Xiong Q, Fan S, Duan L, et al. NCAPH is negatively associated with Mcl‑1 in non‑small cell lung cancer. Mol Med Rep. 2020;22:2916–2924. doi:10.3892/mmr.2020.11359
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhang L, Liu T, et al. Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer. Ann Transl Med. 2020;8(23):1589. doi: 10.21037/atm-20-2305
   PubMed Web of Science ®Google Scholar
• Fogarty LC, Flemmer RT, Geizer BA, et al. Mcl-1 and Bcl-Xl are essential for survival of the developing nervous system. Cell Death Differ. 2019;26(8):1501–1515. doi: 10.1038/s41418-018-0225-1
   PubMed Web of Science ®Google Scholar
• Opferman JT, Letai A, Beard C, et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426(6967):671–676. doi: 10.1038/nature02067
   PubMed Web of Science ®Google Scholar
• Wang X, Bathina M, Lynch J, et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013;27(12):1351–1364. doi: 10.1101/gad.215855.113
   PubMed Web of Science ®Google Scholar
• Gores GJ, Kaufmann SH. Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors: Figure 1. Genes Dev. 2012;26(4):305–311. doi: 10.1101/gad.186189.111
   PubMed Web of Science ®Google Scholar
• Hird AW, Tron AE. Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacol Ther. 2019;198:59–67. doi: 10.1016/j.pharmthera.2019.02.007
   PubMed Web of Science ®Google Scholar
• Shahar N, Larisch S. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resist Updat. 2020;52:100712. doi: 10.1016/j.drup.2020.100712
   PubMed Web of Science ®Google Scholar
• Vaidya T, Desai S, Mahajan A. 8 th edition AJCC and imaging TNM: Time to break-in and assert in the staging process! Indian J Cancer. 2019;56(3):271–273. doi: 10.4103/ijc.IJC_528_18
   PubMed Web of Science ®Google Scholar
• Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775–784. doi: 10.1080/14737140.2018.1489246
   PubMed Web of Science ®Google Scholar
• Liao Y, Yin G, Fan X. The positive lymph node ratio predicts survival in T(1-4)N(1-3)M(0) non-small cell lung cancer: a nomogram using the SEER database. Front Oncol. 2020;10:1356.
   PubMed Web of Science ®Google Scholar
• Yin G, Xiao H, Liao Y, et al. Construction of a nomogram after using propensity score matching to reveal the prognostic benefit of tumor resection of stage IV M1a nonsmall cell lung cancer patients. Cancer Invest. 2020;38(5):277–288. doi: 10.1080/07357907.2020.1753761
   PubMed Web of Science ®Google Scholar
• Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Bio. 1995;128(6):1173–1184. doi: 10.1083/jcb.128.6.1173
   PubMed Web of Science ®Google Scholar
• Jamil S, Stoica C, Hackett TL, et al. MCL-1 localizes to sites of DNA damage and regulates DNA damage response. Cell Cycle. 2010;9(14):2843–2855. doi: 10.4161/cc.9.14.12354
   PubMed Web of Science ®Google Scholar
• Morciano G, Giorgi C, Balestra D, et al. Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death. Mol Biol Cell. 2016;27(1):20–34. doi: 10.1091/mbc.E15-01-0028
   PubMed Web of Science ®Google Scholar
• Sancho M, Leiva D, Lucendo E, et al. Understanding MCL1: from cellular function and regulation to pharmacological inhibition. FEBS J. 2022;289(20):6209–6234. doi: 10.1111/febs.16136
   PubMed Web of Science ®Google Scholar
• Yue S, Li Y, Chen X, et al. FGFR-TKI resistance in cancer: current status and perspectives. J Hematol Oncol. 2021;14(1):23. doi: 10.1186/s13045-021-01040-2
   PubMed Web of Science ®Google Scholar
• Jafarlou M, Shanehbandi D, Dehghan P, et al. Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia. Artif Cells Nanomed Biotechnol. 2018;46:1792–1798.
   PubMed Web of Science ®Google Scholar
• Whitsett TG, Mathews IT, Cardone MH, et al. Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response. Mol Cancer Res. 2014;12:550–559.
   PubMed Web of Science ®Google Scholar
• Fu X, Xie W, Song X, et al. Aberrant expression of deubiquitylating enzyme USP9X predicts poor prognosis in gastric cancer. Clin Res Hepatol Gastroenterol. 2017;41(6):687–692. doi: 10.1016/j.clinre.2017.01.008
   PubMed Web of Science ®Google Scholar
• Yokobori T, Yokoyama Y, Mogi A, et al. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs. Mol Cancer Res. 2014;12(1):32–37. doi: 10.1158/1541-7786.MCR-13-0341
   PubMed Web of Science ®Google Scholar
• Xu C, Liu Y, Huang J, et al. The prognostic significance of MCL1 copy number gain in esophageal squamous cell carcinoma. Oncotarget. 2017;8(50):87699–87709. doi: 10.18632/oncotarget.21181
   PubMedGoogle Scholar